Prevalence and Prognostic Role of PIK3CA/AKT1 Mutations in Chinese Breast Cancer Patients

키워드

참고문헌 (33)

1. Rodon J, "Development of PI3K inhibitors : lessons learned from early clinical trials", Nat Rev Clin Oncol, 10, pp.143~153 (2013)
2. Thorpe LM, "PI3K in cancer : divergent roles of isoforms, modes of activation and therapeutic targeting", Nat Rev Cancer, 15, pp.7~24 (2015)
3. Cancer Genome Atlas Network, "Comprehensive molecular portraits of human breast tumours", Nature, 490, pp.61~70 (2012)
4. Cizkova M, "Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab", Br J Cancer, 108, pp.1807~1809 (2013)
5. Loi S, "Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer", J Natl Cancer Inst, 105, pp.960~967 (2013)
6. Cizkova M, "PIK3R1 underexpression is an independent prognostic marker in breast cancer", BMC Cancer, 13, pp.545~ (2013)
7. Sabine VS, "Mutational analysis of PI3K", AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study, 2014, pp.32, 2951~2958
8. Loibl S, "PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2(her2)therapy in primary HER2-overexpressing breast cancer", J Clin Oncol, 32, pp.3212~3220 (2014)
9. Majewski IJ, "PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer", J Clin Oncol, 33, pp.1334~1339 (2015)
10. Deng L, "Correlation between activation of PI3K", AKT, PLoS One, pp.2015, 10[DOI]
11. Yuan H, "Association of PIK3CA mutation status before and after neoadjuvant chemotherapy with response to chemotherapy in women with breast cancer", Clin Cancer Res, 21, pp.4365~4372 (2015)
12. Papaxoinis G, "Significance of PIK3CA mutations in patients with early breast cancer treated with adjuvant chemotherapy: a Hellenic Cooperative Oncology Group (HeCOG) Study", PLoS One, 10, pp.e0140293~ (2015)
13. Engels CC, "The clinical value of HER-2 overexpression and PIK3CA mutations in the older breast cancer population : a FOCUS study analysis", Breast Cancer Res Treat, 156, pp.361~370 (2016)
14. Xu B, "Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone", Breast Cancer Res, 16, pp.405~ (2014)
15. Hortobagyi GN, "Correlative analysis of genetic alterations and everolimus benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer : Results From BOLERO-2", J Clin Oncol, 34, pp.419~426 (2016)
16. Pang B, "Prognostic role of PIK3CA mutations and their association with hormone receptor expression in breast cancer : a meta-analysis", Sci Rep, 4, pp.6255~ (2014)
17. Guideline Recommendations for Immunohistochemistry Detection in Breast Cancer Group, "Guideline for testing of estrogen and progesterone receptors in breast cancer", Zhonghua Bing Li Xue Za Zhi, 44, pp.237~239 (2015)
18. Guideline Recommendations for HER2 Detection in Breast Cancer Group, "Guidelines for HER2 detection in breast cancer, the 2014 version", Zhonghua Bing Li Xue Za Zhi, 43, pp.262~267 (2014)
19. Goldhirsch A, "Personalizing the treatment of women with early breast cancer : highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013", Ann Oncol, 24, pp.2206~2223 (2013)
20. Gourgou-Bourgade S, "Guidelines for time-to-event end point definitions in breast cancer trials : results of the DATECAN initiative(Definition for the Assessment of Time-toevent Endpoints in CANcer trials)", Ann Oncol, 26, pp.2505~2506 (2015)
21. Ahmad F, "Molecular evaluation of PIK3CA gene mutation in breast cancer : determination of frequency, distribution pattern and its association with clinicopathological findings in Indian patients", Med Oncol, 33, pp.74~ (2016)
22. Takeshita T, "Prognostic role of PIK3CA mutations of cell-free DNA in early-stage triple negative breast cancer", Cancer Sci, 106, pp.1582~1589 (2015)
23. Leo F, "Prognostic factors in the myoepithelial-like spindle cell type of metaplastic breast cancer", Virchows Arch, 469, pp.191~201 (2016)
24. Jacot W, "High EGFR protein expression and exon 9PIK3CA mutations are independent prognostic factors in triple negative breast cancers", BMC Cancer, 15, pp.986~ (2015)
25. Baselga J, "Biomarker analyses in CLEOPATRA : a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer", J Clin Oncol, 32, pp.3753~3761 (2014)
26. Kim JY, "Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes", Oncotarget, 8, pp.27997~28007 (2017)
27. Jensen JD, "PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab", Ann Oncol, 23, pp.2034~2042 (2012)
28. Ibrahim EM, "The predictive and prognostic role of phosphatase phosphoinositol-3(PI3)kinase(PIK3CA)mutation in HER2-positive breast cancer receiving HER2-targeted therapy : a meta-analysis", Breast Cancer Res Treat, 152, pp.463~476 (2015)
29. Loibl S, "PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer : pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab", Ann Oncol, 27, pp.1519~1525 (2016)
30. Yang SX, "New insights on PI3K", AKT pathway alterations and clinical outcomes in breast cancer, 2016, pp.45, 87~96
31. Oda K, "PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation", Cancer Res, 68, pp.8127~8136 (2008)
32. Stemke-Hale K, "An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer", Cancer Res, 68, pp.6084~6091 (2008)
33. Moynahan ME, "Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR(+), HER2(–)advanced breast cancer : results from BOLERO-2", Br J Cancer, 116, pp.726~730 (2017)

관련 논문AI추천